Abstract 215P
Background
mnccRCC had a poor response to VEGF-targeted tyrosine kinase inhibitors (TKIs) and the first-line therapy was still limited. Our real-world study aimed to evaluate the effectiveness of tislelizumab-axitinib combination therapy versus TKI monotherapy as the first-line regimen in patients (pts) with mnccRCC.
Methods
Pts with mnccRCC received first-line therapy were identified between Jul. 2019 and Dec. 2022 in Sun Yat-sen University Cancer Center. Pts received first-line TKI monotherapy (TKI group, mainly sunitinib) or tislelizumab plus axitinib therapy (T+A group). Baseline characteristics, objective response rate (ORR), progression-free survival (PFS), PFS2 (defined as time from initial treatment to progression after first subsequent therapy or any-cause death.) and overall survival (OS) were retrospectively collected. The differences on effectiveness between the two groups were compared.
Results
Totally 39 pts were included, with a median age of 46 (17-72) years. 77.1% had an IMDC intermediate/poor-risk disease. 53.8% had papillary RCC, 19.5% had Mit family translocation RCC, 12.1% had chromophobe RCC and others had unclassified RCC. The median follow-up was 23.7 (18.5-29.0) months. The T+A group (n=20) had a significantly longer PFS compared with the TKI group(n=19) (median PFS (95% CI): 11.0 (8.1-14.0) vs 4.6 (3.0-6.2) months, P<0.001). Similarly, ORR was remarkably improved in the T+A group (40.0% vs 10.5%, P=0.006). The PFS2 did not come to the significant difference between the T+A group and TKI group (median PFS2 (95% CI): 18.6 (NR-NR) vs 12.0 (7.9-16.2) months, P=0.646). Median OS was not reached for T+A group and TKI group (median OS (95% CI): NR vs 39.6 (NR-NR) months, P= 0.176).
Conclusions
Tislelizumab plus axitinib could be an effective first-line regimen option for mnccRCC pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract